GETI.B

210.8

-0.05%↓

CAMX

602

-0.41%↓

BIOAB

308.4

-3.08%↓

EKTA.B

57.05

+2.24%↑

VITR

141.2

+1.66%↑

GETI.B

210.8

-0.05%↓

CAMX

602

-0.41%↓

BIOAB

308.4

-3.08%↓

EKTA.B

57.05

+2.24%↑

VITR

141.2

+1.66%↑

GETI.B

210.8

-0.05%↓

CAMX

602

-0.41%↓

BIOAB

308.4

-3.08%↓

EKTA.B

57.05

+2.24%↑

VITR

141.2

+1.66%↑

GETI.B

210.8

-0.05%↓

CAMX

602

-0.41%↓

BIOAB

308.4

-3.08%↓

EKTA.B

57.05

+2.24%↑

VITR

141.2

+1.66%↑

GETI.B

210.8

-0.05%↓

CAMX

602

-0.41%↓

BIOAB

308.4

-3.08%↓

EKTA.B

57.05

+2.24%↑

VITR

141.2

+1.66%↑

Home・Aktien・Vivesto AB

Vivesto AB

Geschlossen

0.22

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

0.22

Max

0.22

Schlüsselkennzahlen
By Trading Economics
Einkommen	2.3M -7.2M
EPS	-0.013
Angestellte	4

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-4.4M 74M
Vorheriger Eröffnungskurs	0.22
Vorheriger Schlusskurs	0.22

Vivesto AB Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

4. Dez. 2025, 20:41 UTC

Ergebnisse

Wichtige Markttreiber

America's Car-Mart Rises on Better-Than-Expected 2Q Revenue, $300 Million Term Loan

4. Dez. 2025, 18:14 UTC

Akquisitionen, Fusionen, Übernahmen

Big Yellow Says It Will Terminate Takeover Talks With Blackstone

4. Dez. 2025, 17:43 UTC

Wichtige Markttreiber

Akquisitionen, Fusionen, Übernahmen

Brera Holdings Signs Non-Binding Term Sheet to Acquire RockawayX

4. Dez. 2025, 17:01 UTC

Ergebnisse

TD Bank Pushes Up Dividend After Underlying Earnings, Revenue Beat Expectations -- Update

4. Dez. 2025, 23:45 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market, Japan Earnings -- Market Talk

4. Dez. 2025, 23:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. Dez. 2025, 21:54 UTC

Market Talk

Global Equities Roundup: Market Talk

4. Dez. 2025, 21:54 UTC

Market Talk

Warehouse's Strategy to Lift Margins Easier Said Then Done -- Market Talk

4. Dez. 2025, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

4. Dez. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

4. Dez. 2025, 21:48 UTC

Market Talk

Scales Hits Mark With Earnings Guidance -- Market Talk

4. Dez. 2025, 21:37 UTC

Ergebnisse

Aerospace Start-Up Beta Posts Its First Earnings Report. The Stock Rises. -- Barrons.com

4. Dez. 2025, 21:36 UTC

Ergebnisse

These Stocks Moved the Most Today: Meta Platforms, Salesforce, Snowflake, UiPath, Micron, Dollar General, Kroger, and More -- Barrons.com

4. Dez. 2025, 20:15 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

4. Dez. 2025, 20:15 UTC

Market Talk

Think Tank Calls For Bank of Canada Rate Hold Next Week -- Market Talk

4. Dez. 2025, 20:04 UTC

Market Talk

Natural Gas Futures Extend Gains as U.S. Grows Cold -- Market Talk

4. Dez. 2025, 19:54 UTC

Market Talk

Oil Futures Bolstered by Lasting Ukraine War, U.S. Macro Outlook -- Market Talk

4. Dez. 2025, 19:44 UTC

Akquisitionen, Fusionen, Übernahmen

EQB CEO: PC Financial Deal Adds Scale to Compete With Larger Canadian Banks

4. Dez. 2025, 19:44 UTC

Akquisitionen, Fusionen, Übernahmen

EQB CEO: PC Financial Tie-Up Brings Scale to Reach More Customers

4. Dez. 2025, 19:44 UTC

Akquisitionen, Fusionen, Übernahmen

Equitable Bank Deal for PC Financial Adds Heft to Compete With Canada's Big Banks -- Interview

4. Dez. 2025, 19:33 UTC

Market Talk

Gold Inches Higher as Traders Continue to Mull ADP Jobs Report -- Market Talk

4. Dez. 2025, 19:01 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Raises Concerns About Netflix's Bid for Warner Bros. Discovery -- WSJ

4. Dez. 2025, 19:01 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Wrote to Warner Bros. Discovery Again Wednesday -- WSJ

4. Dez. 2025, 19:01 UTC

Akquisitionen, Fusionen, Übernahmen

Paramount Wrote Netflix Deal With Warner Bros. Would Likely 'Never Close,' Monday Letter Says -- WSJ

4. Dez. 2025, 19:01 UTC

Akquisitionen, Fusionen, Übernahmen

Another Round of Bids for Warner Bros. Discovery Due Thursday, Sources Say -- WSJ

4. Dez. 2025, 18:58 UTC

Market Talk

U.S.-Venezuela Military Tension Expected to Lift Oil Prices -- Market Talk

4. Dez. 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

4. Dez. 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

4. Dez. 2025, 16:41 UTC

Market Talk

Gold Rises as Traders Await U.S. Inflation Data -- Market Talk

4. Dez. 2025, 16:33 UTC

Market Talk

Ergebnisse

Salesforce Customers Are Gaining Confidence in Agentforce -- Market Talk

Peer-Vergleich

Kursveränderung

Vivesto AB Prognose

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Vivesto AB

Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company's products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer. its animal health product portfolio includes Paccal Vet, a formulation of paclitaxel with its XR-17 encapsulation technology for the treatment of canine mastocytoma; and Doxophos Vet, a patented formulation of doxorubicin to treat lymphoma. The company was formerly known as Oasmia Pharmaceutical AB (publ) and changed its name to Vivesto AB in March 2022. Vivesto AB was incorporated in 1988 and is headquartered in Solna, Sweden.